Related Experiment Video
Updated: Jun 24, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
ANCA-associated vasculitides: pathogenetic aspects and current evidence-based therapy
1University Hospital of Schleswig-Holstein, Campus Luebeck, Dept. of Rheumatology and Rheumaklinik Bad Bramstedt, Ratzeburger Allee 160, 23538 Luebeck, Germany. julia.holle@uk-sh.de
Abstract:
A lot of progress has been made regarding the therapy of ANCA-associated vasculitides in the past decades. Cyclophosphamide still is standard therapy for remission induction in generalized disease, however, duration and cumulative dose of cyclophosphamide have been curtailed successfully to reduce toxicity. MTX is a safe alternative for remission induction in early systemic disease and medications available for remission maintenance have been extended. Rituximab and TNFalpha-antagonists represent promising options for refractory disease. The current evidence of therapy of ANCA-associated vasculitides is summarized in this review.
Related Concept Videos
Atherosclerosis III: Management
Mechanism of Angiogenesis
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune system...
Cytotoxic Edema: Pathophysiology
Myocarditis III: Medical Management
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations